Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, Monteiro FSM, Cattrini C, Landmesser J, Messina C, Zgura A, Rebuzzi SE, Soares A, Carrozza F, Ansari J, Grillone F, Küronya Z, Incorvaia L, Bhuva D, Ortega C, Nasso C, Kanesvaran R, Zampiva I, Porta C, Buti S, Santoni M. Roviello G, et al. Among authors: rebuzzi se. Cancer Immunol Immunother. 2025 Jan 3;74(2):65. doi: 10.1007/s00262-024-03897-x. Cancer Immunol Immunother. 2025. PMID: 39752009 Free PMC article.
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
Maiorano BA, Catalano M, Mercinelli C, Roviello G, Maruzzo M, De Giorgi U, Chiellino S, Sbrana A, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Napoli MD, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Puglisi S, Signori A, Necchi A, Banna GL, Fornarini G, Buti S, Rebuzzi SE. Maiorano BA, et al. Among authors: rebuzzi se. Clin Genitourin Cancer. 2024 Nov 10;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39603144
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study.
Guida A, Gili A, Mosillo C, Maruzzo M, Lai E, Pierantoni F, Bimbatti D, Basso U, Fornarini G, Rebuzzi SE, Calabrò F, Cerbone L, Caserta C, Sirgiovanni G, Serafin D, Caffo O, Scagliarini S, Bracarda S. Guida A, et al. Among authors: rebuzzi se. Clin Genitourin Cancer. 2024 Dec;22(6):102225. doi: 10.1016/j.clgc.2024.102225. Epub 2024 Sep 14. Clin Genitourin Cancer. 2024. PMID: 39405768
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Fiala O, et al. Among authors: rebuzzi se. Target Oncol. 2024 Nov;19(6):905-915. doi: 10.1007/s11523-024-01099-0. Epub 2024 Oct 1. Target Oncol. 2024. PMID: 39354179 Free PMC article.
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.
Damassi A, Cremante M, Signori A, Rebuzzi SE, Malgeri A, Napoli MD, Caffo O, Vignani F, Cavo A, Roviello G, Prati V, Tudini M, Atzori F, Messina M, Morelli F, Prati G, Nolè F, Catalano F, Murianni V, Rescigno P, Banna GL, Fornarini G, Buti S. Damassi A, et al. Among authors: rebuzzi se. Immunotherapy. 2024;16(18-19):1095-1103. doi: 10.1080/1750743X.2024.2385881. Epub 2024 Aug 19. Immunotherapy. 2024. PMID: 39155821
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.
Anpalakhan S, Banna GL, Rebuzzi SE, Fornarini G, Maruzzo M, Zucali PA, Catalano F, Antonj L, Tudini M, Fratino L, Malgeri A, Rescigno P, Signori A, Acunzo A, Silini EM, Mazzaschi G, Buti S. Anpalakhan S, et al. Among authors: rebuzzi se. Immunotherapy. 2024;16(14-15):963-973. doi: 10.1080/1750743X.2024.2382666. Epub 2024 Aug 6. Immunotherapy. 2024. PMID: 39105621
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, Fornarini G, Zucali PA, Claps M, Chiellino S, Zampiva I, Pipitone S, Ricotta R, Sorarù M, Mollica V, Tudini M, Fratino L, Prati V, Caffo O, Atzori F, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Di Napoli M, Malgeri A, Naglieri E, Signori A, Banna GL, Rescigno P, Cerbone L, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: rebuzzi se. Front Immunol. 2024 Jul 5;15:1361010. doi: 10.3389/fimmu.2024.1361010. eCollection 2024. Front Immunol. 2024. PMID: 39034992 Free PMC article.
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.
Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, Conteduca V, Rebuzzi SE, Beninato T, Venturi G, Doni L, Verzoni E, Puglisi S, Landriscina M, Porta C, Manfredi F, Caffo O, De Giorgi U, Fogli S, Danesi R. Del Re M, et al. Among authors: rebuzzi se. Clin Genitourin Cancer. 2024 Oct;22(5):102147. doi: 10.1016/j.clgc.2024.102147. Epub 2024 Jun 27. Clin Genitourin Cancer. 2024. PMID: 39030142
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Messina C, Catalano M, Roviello G, Gandini A, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucal PA, Masini C, Naglieri E, Procopio G, Milella M, Catalano F, Fratino L, Pipitone S, Ricotta R, Panni S, Mollica V, Soraru M, Prati V, Atzori F, Di Napoli M, Messina M, Morelli F, Prati G, Nole F, Malgeri A, Tudini M, Vignani F, Cavo A, Signori A, Banna GL, Rescigno P, Buti S, Rebuzzi SE, Fornarini G. Messina C, et al. Among authors: rebuzzi se. Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2. Cancer Immunol Immunother. 2024. PMID: 38954006 Free PMC article.
100 results